Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aveo Pharmaceuticals has reported encouraging preclinical data that demonstrated the potential of AV-412 as a therapeutic agent for the treatment of drug-resistant cancers expressing EGFR and ErbB2 mutations, such as non-small cell lung cancer and breast cancer.
Subscribe to our email newsletter
AV-412 produced potent anti-tumor effects in several variants of EGFR kinase, including L858R and T790M double mutants, which are known to be resistant to erlotinib (Tarceva) and gefitinib (Iressa). In addition, AV-412 also demonstrated significant anti-tumor effects on the ErbB2-overexpressing breast cancer KPL-4 cell line, which is resistant to gefitinib.
AV-412 is a next generation oral tyrosine kinase inhibitor of the EGFR and ErbB2 mutations that could potentially treat patients with drug-resistant cancers. The drug is currently being evaluated in ongoing Phase I clinical trials with data expected in 2008.
Tuan Ha-Ngoc, president and CEO of Aveo Pharmaceuticals said: “This important preclinical data showing AV-412’s potent inhibition of the EGFR L858R and T790M mutations, which are resistant to the currently available targeted therapies, provide additional insight into the development opportunities and clinical potential of this novel, potent kinase inhibitor. We look forward to advancing the clinical program for AV-412 and to obtaining the data from our ongoing Phase I clinical trials of AV-412 next year.”